[HTML][HTML] The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - frontiersin.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
Lu-177-based peptide receptor radionuclide therapy for advanced neuroendocrine tumors
K Kim, SJ Kim - Nuclear medicine and molecular imaging, 2018 - Springer
Peptide receptor radionuclide therapy (PRRT) is a systemic cytotoxic radiation therapy using
a compound of β-emitting radionuclide chelated to a peptide for the treatment of tumor with …
a compound of β-emitting radionuclide chelated to a peptide for the treatment of tumor with …
[HTML][HTML] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
MN Becx, NS Minczeles, T Brabander, WW de Herder… - Cancers, 2022 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …
Peptide receptor radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors—from oncology perspective
A Kolasińska-Ćwikła, A Łowczak… - Nuclear Medicine …, 2018 - journals.viamedica.pl
Abstract Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted
therapy which is performed by using a small peptide (somatostatin analogue—SSA) that is …
therapy which is performed by using a small peptide (somatostatin analogue—SSA) that is …
[HTML][HTML] Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra …
A Sabet, J Nagarajah, AS Dogan, HJ Biersack… - EJNMMI research, 2013 - Springer
Background Peptide receptor radionuclide therapy (PRRT) with 177 Lu-[DOTA 0, Tyr 3]
octreotate (177 Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 …
octreotate (177 Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 …
Peptide receptor radionuclide therapy
J Hofland, T Brabander, FA Verburg… - The Journal of …, 2022 - academic.oup.com
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …
positron emission tomography or single photon emission computed tomography imaging …
Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy
J Kennedy, A Chicheportiche, Z Keidar - Seminars in nuclear medicine, 2022 - Elsevier
Neuroendocrine tumors (NETs) are uncommon malignancies of increasing incidence and
prevalence. As these slow growing tumors usually overexpress somatostatin receptors …
prevalence. As these slow growing tumors usually overexpress somatostatin receptors …
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
AT Kendi, TR Halfdanarson, A Packard… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
[HTML][HTML] Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study
G Sistani, DEK Sutherland, A Mujoomdar… - Current …, 2020 - mdpi.com
Peptide receptor radionuclide therapy (PRRT) has been recently established as a treatment
option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including …
option for progressive gastro-entero-pancreatic neuroendocrine tumors (NETs) including …
[HTML][HTML] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu] Lu-DOTA-TATE for the treatment of neuroendocrine tumours
L Geenen, J Nonnekens, M Konijnenberg… - Nuclear medicine and …, 2021 - Elsevier
Peptide receptor radionuclide therapy (PRRT) is used for the treatment of patients with
unresectable or metastasized somatostatin receptor type 2 (SSTR 2)-expressing …
unresectable or metastasized somatostatin receptor type 2 (SSTR 2)-expressing …